
How Cancer Research Horizons is building the future of childhood cancer medicines
Episode 210
Cancer is still the leading cause of death by disease in children and young people — yet in the last twenty years, only a handful of drugs have been approved specifically to treat it. Most paediatric cancer treatments are simply adult drugs, repurposed, often at real long-term cost to the children who survive. Today's guest is working to change that, and much more besides. Tony Hickson is Chief Business Officer for Cancer Research Horizons, Cancer Research UK's innovation engine, responsible for turning early-stage science into new treatments, diagnostics, and start-up companies. Tony's career spans big pharma, university tech transfer, and now the translational front line of cancer research, and he's helped build dozens of spinouts along the way. We'll talk about why charity and pharma need each other more than ever, and about C-Further, a bold new push to finally build medicines made for children, not borrowed from adults. 01:25 Meet Tony Hickson 05:21 What sets Cancer Research Horizons apart from tech transfer offices 12:17 Myrix Bio's exit to Novartis, a standout story 15:54 Can patient benefit and commercial success align 28:53 Inside C-Further's first two therapeutic programs 41:19 How researchers and partners can get involved Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!
Publisher
Beyond Biotech - the podcast from Labiotech
Published
August 14, 2026
Duration
43 min
Format
Podcast
Category
Issues · Tech News
Source
RSS feed
Host
Labiotech
Beyond Biotech - the podcast from Labiotech
@beyondbiotechthepodcastfroml
#cancerresearchhorizons #building #childhoodcancermedicines
